

Hartmut DÄjhner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8194270/publications.pdf>

Version: 2024-02-01

595
papers

74,579
citations

729

120
h-index

609

259
g-index

609
all docs

609
docs citations

609
times ranked

40111
citing authors

#	ARTICLE	IF	CITATIONS
1	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. <i>Blood</i> , 2023, 141, 156-167.	0.6	27
2	Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy. <i>Haematologica</i> , 2022, 107, 604-614.	1.7	11
3	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. <i>Blood</i> , 2022, 139, 323-332.	0.6	80
4	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99.	3.3	42
5	Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 236-250.	0.2	10
6	Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. <i>Nature Communications</i> , 2022, 13, 1009.	5.8	28
7	Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. <i>Journal of Clinical Oncology</i> , 2022, 40, 855-865.	0.8	86
8	Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2022, 386, 1519-1531.	13.9	186
9	Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. <i>Blood Advances</i> , 2022, 6, 5345-5355.	2.5	24
10	Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. <i>Blood</i> , 2022, 140, 285-289.	0.6	15
11	Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib + azacitidine or placebo + azacitidine. <i>Journal of Clinical Oncology</i> , 2022, 40, e19024-e19024.	0.8	0
12	Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 7042-7042.	0.8	0
13	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
14	Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. <i>Journal of Clinical Oncology</i> , 2022, 40, 7019-7019.	0.8	0
15	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.	0.6	805
16	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. <i>Leukemia</i> , 2021, 35, 62-74.	3.3	63
17	TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. <i>Leukemia</i> , 2021, 35, 389-403.	3.3	26
18	Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. <i>Leukemia</i> , 2021, 35, 628-631.	3.3	8

#	ARTICLE	IF	CITATIONS
19	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. <i>Blood</i> , 2021, 137, 1792-1803.	0.6	123
20	Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 57-65.	0.8	118
21	Germline variants drive myelodysplastic syndrome in young adults. <i>Leukemia</i> , 2021, 35, 2439-2444.	3.3	43
22	Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. <i>IScience</i> , 2021, 24, 102089.	1.9	14
23	Deregulated expression of circular RNAs in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1490-1503.	2.5	16
24	Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2021, , .	1.7	2
25	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	3.3	51
26	Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique. <i>Annals of Hematology</i> , 2021, 100, 1983-1993.	0.8	2
27	Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. <i>Blood Advances</i> , 2021, 5, 2294-2304.	2.5	60
28	Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7011-7011.	0.8	3
29	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. <i>Haematologica</i> , 2021, 106, 2986-2989.	1.7	5
30	Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2391-2402.	2.5	10
31	Towards precision medicine for AML. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 577-590.	12.5	138
32	Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7018-7018.	0.8	6
33	Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7014-7014.	0.8	2
34	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021, 137, 3093-3104.	0.6	91
35	A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-12.	0.6	9
36	Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. <i>Journal of Hematology and Oncology</i> , 2021, 14, 133.	6.9	13

#	ARTICLE	IF	CITATIONS
37	The EHA Research Roadmap: Malignant Myeloid Diseases. HemaSphere, 2021, 5, e635.	1.2	2
38	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. HemaSphere, 2021, 5, e617.	1.2	10
39	Survivin™ Acute Myeloid Leukaemia – A Personalised Target for inv(16) Patients. International Journal of Molecular Sciences, 2021, 22, 10482.	1.8	4
40	Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica, 2021, 106, 3240-3244.	1.7	6
41	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nature Communications, 2021, 12, 5395.	5.8	15
42	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 164.	2.8	29
43	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncology, The, 2021, 22, 1597-1608.	5.1	90
44	<i>COVID-19 Vaccination after Allogeneic Stem Cell Transplantation: Real Word Data on Safety and Efficacy. a Single Center Experience.</i>. Blood, 2021, 138, 4868-4868.	0.6	0
45	Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. Blood, 2021, 138, 608-608.	0.6	0
46	Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial. Blood, 2021, 138, 871-871.	0.6	8
47	Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase 1b/II MPNSG0212 (POMINC) Trial. Blood, 2021, 138, 4637-4637.	0.6	0
48	Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study. Blood, 2021, 138, 369-369.	0.6	8
49	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications. Blood, 2021, 138, 692-692.	0.6	1
50	Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation. Blood, 2021, 138, 1276-1276.	0.6	1
51	Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance. Blood, 2021, 138, 5031-5031.	0.6	0
52	Randomized Phase II Study of All-<i>Trans</i> Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of <i>TP53</i> Status. Blood, 2021, 138, 2380-2380.	0.6	2
53	Prognostic Impact of <i>NPM1</i> and <i>FLT3</i> Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance. Blood. 2021, 138, 804-804.	0.6	4
54	Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. Blood, 2021, 138, 3438-3438.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Machine Learning of Genomic Factors in 1,961 Patients with Acute Myeloid Leukemia Identifies Patients with Very Good or Very Poor Prognosis Who Do Not Benefit from Allogeneic Hematopoietic Cell Transplant in First Remission. <i>Blood</i> , 2021, 138, 225-225.	0.6	2
56	Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 33-33.	0.6	0
57	Midostaurin in Patients (Pts) with Newly Diagnosed <i>FLT3</i> -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial. <i>Blood</i> , 2021, 138, 1303-1303.	0.6	1
58	AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. <i>Blood</i> , 2021, 138, 697-697.	0.6	10
59	The microRNA miR-196b acts as a tumor suppressor in Cdx2-driven acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e285-e289.	1.7	8
60	Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). <i>Leukemia</i> , 2020, 34, 404-415.	3.3	16
61	Granulocyte transfusions â€“ bridging to allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 481-484.	0.6	4
62	Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. <i>Leukemia</i> , 2020, 34, 115-127.	3.3	23
63	Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML). <i>Leukemia</i> , 2020, 34, 630-634.	3.3	2
64	Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. <i>Haematologica</i> , 2020, 105, 1379-1390.	1.7	24
65	Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. <i>Leukemia</i> , 2020, 34, 1177-1181.	3.3	6
66	Gemtuzumab Ozogamicin in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 623-632.	0.8	73
67	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 Å— 2, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 257-270.	0.8	63
68	MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells. <i>Leukemia</i> , 2020, 34, 1253-1265.	3.3	12
69	Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis. <i>Leukemia</i> , 2020, 34, 1027-1037.	3.3	16
70	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	2.5	34
71	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	13.9	1,407
72	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i> -mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020, 136, 3041-3050.	0.6	73

#	ARTICLE	IF	CITATIONS
73	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. <i>Blood Advances</i> , 2020, 4, 6342-6352.	2.5	45
74	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 2020, 383, 2526-2537.	13.9	265
75	DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy. <i>Scientific Data</i> , 2020, 7, 133.	2.4	6
76	Model-Based Optimal AML Consolidation Treatment. <i>IEEE Transactions on Biomedical Engineering</i> , 2020, 67, 3296-3306.	2.5	7
77	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. <i>Blood</i> , 2020, 135, 2402-2412.	0.6	83
78	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
79	Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1551-1560.	0.8	15
80	Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: Impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the outcomes. <i>Transplant Infectious Disease</i> , 2020, 22, e13276.	0.7	12
81	Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). <i>Haematologica</i> , 2020, 105, 2598-2607.	1.7	44
82	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. <i>Leukemia</i> , 2020, 34, 2038-2050.	3.3	38
83	Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. <i>Leukemia</i> , 2020, 34, 1038-1051.	3.3	24
84	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. <i>Haematologica</i> , 2020, 105, 2440-2447.	1.7	31
85	Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 629-640.	2.0	11
86	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	0.6	127
87	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	1.7	91
88	Molecular Characterization of Clinical Response and Relapse in Patients with <i>IDH1</i> -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine. <i>Blood</i> , 2020, 136, 49-51.	0.6	1
89	CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial. <i>Blood</i> , 2020, 136, 38-40.	0.6	7
90	CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial. <i>Blood</i> , 2020, 136, 32-33.	0.6	12

#	ARTICLE	IF	CITATIONS
91	Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 1018-1021.	1.2	21
92	Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders. <i>International Journal of Cancer</i> , 2019, 144, 1135-1146.	2.3	12
93	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. <i>Science</i> , 2019, 365, 599-604.	6.0	265
94	Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S217-S218.	0.2	3
95	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , 2019, 134, 1608-1618.	0.6	85
96	getITD for FLT3-ITD-based MRD monitoring in AML. <i>Leukemia</i> , 2019, 33, 2535-2539.	3.3	45
97	Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, e434-e437.	1.7	144
98	IGF1R as druggable target mediating PI3K-Î inhibitor resistance in a murine model of chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 534-547.	0.6	51
99	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. <i>Nature Communications</i> , 2019, 10, 2031.	5.8	87
100	Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 2183-2194.	3.3	19
101	Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. <i>Journal of Experimental Medicine</i> , 2019, 216, 966-981.	4.2	91
102	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019, 133, 1630-1643.	0.6	393
103	The ParaHox gene Cdx4 induces acute erythroid leukemia in mice. <i>Blood Advances</i> , 2019, 3, 3729-3739.	2.5	4
104	Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. <i>Haematologica</i> , 2019, 104, e63-e64.	1.7	4
105	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. <i>Blood</i> , 2019, 133, 840-851.	0.6	228
106	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 583-587.	1.2	5
107	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1124-1134.	3.3	29
108	FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. <i>Blood</i> , 2019, 133, 830-839.	0.6	56

#	ARTICLE	IF	CITATIONS
109	Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany. <i>Blood</i> , 2019, 134, 3893-3893.	0.6	1
110	Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapse after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 184-184.	0.6	2
111	Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na ⁺ ve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles. <i>Blood</i> , 2019, 134, 2591-2591.	0.6	12
112	Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia. <i>Blood</i> , 2019, 134, 672-672.	0.6	11
113	Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling. <i>Blood</i> , 2019, 134, 1392-1392.	0.6	6
114	Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSC 26-16/AML-VIVA): Results of the Safety Run-in Phase I. <i>Blood</i> , 2019, 134, 1382-1382.	0.6	11
115	Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. <i>Blood</i> , 2019, 134, 643-643.	0.6	37
116	The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission. <i>Blood</i> , 2019, 134, LBA-3-LBA-3.	0.6	68
117	Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSC). <i>Blood</i> , 2019, 134, 2740-2740.	0.6	0
118	Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors. <i>Blood</i> , 2019, 134, 4275-4275.	0.6	0
119	Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2. <i>Blood</i> , 2019, 134, 1507-1507.	0.6	1
120	Exome Sequencing of Relapsed Multiple Myeloma Combined with Pooled CRISPR/Cas9 Screens Identifies Gene Mutations Associated with Drug-Specific Resistance. <i>Blood</i> , 2019, 134, 809-809.	0.6	0
121	Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na ⁺ ve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study. <i>Blood</i> , 2019, 134, 4235-4235.	0.6	1
122	Telomere Shortening By Terc Knockout in the E μ -TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival. <i>Blood</i> , 2019, 134, 1732-1732.	0.6	0
123	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	0.6	1,069
124	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. <i>Leukemia and Lymphoma</i> , 2018, 59, 1614-1623.	0.6	12
125	<i>NFATC1</i> activation by <i>DNA</i> hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. <i>International Journal of Cancer</i> , 2018, 142, 322-333.	2.3	33
126	Chromothripsis is linked to <i>TP53</i> alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. <i>Haematologica</i> , 2018, 103, e17-e20.	1.7	53

#	ARTICLE	IF	CITATIONS
127	Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 246-255.	1.7	7
128	Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. <i>Leukemia</i> , 2018, 32, 2546-2557.	3.3	101
129	Phase II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSC 17-10 CIARA trial). <i>British Journal of Haematology</i> , 2018, 183, 235-241.	1.2	2
130	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. <i>Blood</i> , 2018, 132, 1703-1713.	0.6	237
131	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 889-903.	5.1	205
132	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSC 11-08 trial. <i>Leukemia</i> , 2018, 32, 1621-1630.	3.3	81
133	Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions. <i>Blood</i> , 2018, 132, 560-560.	0.6	51
134	Expression of PD-L1 in Leukemic Progenitor Cells Defines NPM1 Mutated AML As a Potential Subgroup for PD1/PD-L1 Directed Immunotherapy. <i>Blood</i> , 2018, 132, 2734-2734.	0.6	1
135	FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 2800-2800.	0.6	6
136	Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4430-4430.	0.6	1
137	Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSC 09-09 Phase-III Study. <i>Blood</i> , 2018, 132, 81-81.	0.6	5
138	A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients. <i>Blood</i> , 2018, 132, 2765-2765.	0.6	2
139	NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23. <i>Blood</i> , 2018, 132, 946-946.	0.6	1
140	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSC 16-10 Trial of the German-Austrian Study Group. <i>Blood</i> , 2018, 132, 1501-1501.	0.6	3
141	Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). <i>Blood</i> , 2018, 132, 1534-1534.	0.6	1
142	Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial. <i>Blood</i> , 2018, 132, 720-720.	0.6	4
143	Members of the microRNA-106a-363 Cluster Associate with Unfavorable Outcome in Adult Acute Myeloid Leukemia Patients and Promote Leukemogenesis in vivo through Increased Metabolic Activity. <i>Blood</i> , 2018, 132, 3924-3924.	0.6	2
144	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). <i>Blood</i> , 2018, 132, 435-435.	0.6	3

#	ARTICLE	IF	CITATIONS
145	Deregulated Expression of Circular RNAs in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 3894-3894.	0.6	2
146	MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2627-2627.	0.6	3
147	Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: The Role of Calcineurin Inhibitors. <i>Blood</i> , 2018, 132, 4601-4601.	0.6	0
148	KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML). <i>Blood</i> , 2018, 132, 1535-1535.	0.6	14
149	BRCA1/2 Containing Complex 3 (BRCC36) Is Recurrently Mutated in AML with t(8;21) and Associated with Increased Sensitivity to Chemotherapy through Impairment of the DNA Damage Repair Pathway. <i>Blood</i> , 2018, 132, 1487-1487.	0.6	0
150	Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2018, 132, 4429-4429.	0.6	0
151	The Non-Canonical, R-Loop Regulatory Function of PIWIL4 Maintains Genomic Integrity and Leukemic Potential of AML Cells. <i>Blood</i> , 2018, 132, 879-879.	0.6	0
152	Risk Factors Determining the Outcome of Critically Ill Allogeneic Hematopoietic Stem Cell Transplantation Patients: Time to Step Down?. <i>Blood</i> , 2018, 132, 2135-2135.	0.6	0
153	Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. <i>Blood</i> , 2018, 132, 3103-3103.	0.6	0
154	In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific?. <i>Blood</i> , 2018, 132, 3892-3892.	0.6	0
155	MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy. <i>Blood</i> , 2018, 132, 1866-1866.	0.6	0
156	Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option. <i>Blood</i> , 2018, 132, 1580-1580.	0.6	0
157	Treg Downregulation Was Associated with Augmentation of T Cell Responses Against Immunogenic Antigens and Clinical Responses in Patients with Hematological Malignancies after Donor Lymphocyte Infusion (DLI). <i>Blood</i> , 2018, 132, 3423-3423.	0.6	0
158	Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification. <i>Blood</i> , 2018, 132, 994-994.	0.6	0
159	Precision oncology for acute myeloid leukemia using a knowledge bank approach. <i>Nature Genetics</i> , 2017, 49, 332-340.	9.4	229
160	Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. <i>Journal of Clinical Oncology</i> , 2017, 35, 934-946.	0.8	372
161	Recognition of familial myeloid neoplasia in adults. <i>Seminars in Hematology</i> , 2017, 54, 60-68.	1.8	37
162	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	13.9	1,628

#	ARTICLE	IF	CITATIONS
163	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2017, 23, 5292-5301.	3.2	27
164	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	0.6	4,375
165	Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. <i>British Journal of Haematology</i> , 2017, 179, 342-346.	1.2	2
166	Associations between dyadic coping and supportive care needs: findings from a study with hematologic cancer patients and their partners. <i>Supportive Care in Cancer</i> , 2017, 25, 1445-1454.	1.0	24
167	Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSC Bio). <i>Annals of Hematology</i> , 2017, 96, 1993-2003.	0.8	108
168	Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 2039-2047.	1.7	72
169	Aberrantly expressed TET1 in T-ALL regulates DNA repair and leukemic growth via maintenance of 5-hydroxymethylome and can be antagonized by the parp inhibitor Olaparib. <i>Experimental Hematology</i> , 2017, 53, S129-S130.	0.2	0
170	Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. <i>Lancet Haematology</i> , 2017, 4, e475-e486.	2.2	45
171	Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition. <i>Haematologica</i> , 2017, 102, e499-e501.	1.7	26
172	Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2172-2177.	2.0	59
173	The miRNA-193B is a potent tumor-suppressor and a biomarker for poor prognosis in acute myeloid leukemia. <i>Experimental Hematology</i> , 2017, 53, S52.	0.2	0
174	Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. <i>Blood</i> , 2017, 130, 1477-1480.	0.6	63
175	Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2017, 377, 1901-1903.	13.9	32
176	Azacitidine in adult patients with acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 116, 159-177.	2.0	42
177	Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1412-1423.	0.6	5
178	Dyadic coping of patients with hematologic malignancies and their partners and its relation to quality of life – a longitudinal study. <i>Leukemia and Lymphoma</i> , 2017, 58, 655-665.	0.6	40
179	Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. <i>International Journal of Molecular Sciences</i> , 2017, 18, 415.	1.8	45
180	Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. <i>BMC Cancer</i> , 2017, 17, 852.	1.1	57

#	ARTICLE	IF	CITATIONS
181	Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. <i>Oncotarget</i> , 2017, 8, 7678-7690.	0.8	11
182	Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses. <i>Theranostics</i> , 2017, 7, 1705-1718.	4.6	13
183	Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial. <i>Blood</i> , 2017, 130, 726-726.	0.6	20
184	Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 95163-95175.	0.8	7
185	<i>Protein phosphatase 4 regulatory subunit 2 (PPP4R2)</i> is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair. <i>Oncotarget</i> , 2017, 8, 95038-95053.	0.8	8
186	Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 253-260.	1.1	19
187	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. <i>Haematologica</i> , 2016, 101, 839-845.	1.7	22
188	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. <i>Blood</i> , 2016, 127, 208-215.	0.6	571
189	Genomic Classification in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 900-901.	13.9	134
190	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. <i>Annals of Hematology</i> , 2016, 95, 1931-1942.	0.8	61
191	Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 3758-3765.	0.8	142
192	MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development. <i>Experimental Hematology</i> , 2016, 44, 1166-1171.	0.2	18
193	MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses. <i>Haematologica</i> , 2016, 101, e454-e456.	1.7	7
194	The genomic landscape of core-binding factor acute myeloid leukemias. <i>Nature Genetics</i> , 2016, 48, 1551-1556.	9.4	215
195	Genomic Classification and Prognosis in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 2209-2221.	13.9	3,067
196	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , 2016, 22, 792-799.	15.2	322
197	Kruppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling. <i>Haematologica</i> , 2016, 101, e249-e253.	1.7	26
198	Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks. <i>Epigenetics</i> , 2016, 11, 517-525.	1.3	22

#	ARTICLE	IF	CITATIONS
199	DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2016, 48, 253-264.	9.4	254
200	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	1.7	67
201	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSC). <i>Blood</i> , 2016, 128, 1207-1207.	0.6	10
202	CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A-Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial. <i>Blood</i> , 2016, 128, 1608-1608.	0.6	14
203	Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR). <i>Blood</i> , 2016, 128, 1638-1638.	0.6	2
204	In Vivo modeling of Resistance to PI3KÎ Inhibitor Treatment Using EÂµTCL1-Tg Tumor Transfer Model. <i>Blood</i> , 2016, 128, 190-190.	0.6	7
205	Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpmsg-0212 Trial (NCT01644110). <i>Blood</i> , 2016, 128, 1939-1939.	0.6	5
206	Eculizumab Therapy of Adult TA-TMA: A High Response Rate Is Associated with a High Infection-Related Mortality. <i>Blood</i> , 2016, 128, 2255-2255.	0.6	5
207	Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR). <i>Blood</i> , 2016, 128, 2859-2859.	0.6	7
208	Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group. <i>Blood</i> , 2016, 128, 3227-3227.	0.6	19
209	Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 337-337.	0.6	5
210	Specific Immune Responses for Leukemia-Associated Antigens Against Myeloid Leukemic Cells Are Increased By Immune Checkpoint Inhibition. <i>Blood</i> , 2016, 128, 4054-4054.	0.6	2
211	The PARP Inhibitor Olaparib Antagonizes Leukemic Growth Induced By TET1 Overexpression in AML1-ETO Positive Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4063-4063.	0.6	3
212	Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). <i>Blood</i> , 2016, 128, 4382-4382.	0.6	11
213	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. <i>Blood</i> , 2016, 128, 449-449.	0.6	18
214	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. <i>Blood</i> , 2016, 128, 589-589.	0.6	11
215	Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial. <i>Blood</i> , 2016, 128, 682-682.	0.6	3
216	The Methylcytosine Dioxygenase TET3 Is Aberrantly Expressed in Acute Myeloid Leukemia and Promotes AML Growth. <i>Blood</i> , 2016, 128, 771-771.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. <i>Oncotarget</i> , 2016, 7, 49539-49551.	0.8	12
218	VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice. <i>Oncotarget</i> , 2016, 7, 86889-86901.	0.8	6
219	Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	0.7	1
220	Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged \geq 75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study. <i>Blood</i> , 2016, 128, 2818-2818.	0.6	1
221	Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 599-599.	0.6	0
222	TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be Antagonized By the PARP Inhibitor Olaparib. <i>Blood</i> , 2016, 128, 737-737.	0.6	0
223	The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1534-1534.	0.6	1
224	Two Long Non-Coding RNAs Are Sufficient to Classify and Significantly Predict In Vivo Engraftment Potential and LSC Properties of Human Acute Myeloid Leukemia Cells. <i>Blood</i> , 2016, 128, 2880-2880.	0.6	0
225	Peptide Vaccination Against Cytomegalovirus (CMV) Elicits Immunological and Clinical Responses after Allogeneic Stem Cell Transplantation Even from a CMV Seronegative Donor. <i>Blood</i> , 2016, 128, 2519-2519.	0.6	0
226	The Human Specific microRNA-941 Is a Key Member of a microRNA Signature of Functionally Validated Leukemic Stem Cells from Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2837-2837.	0.6	0
227	Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2016, 128, 4394-4394.	0.6	1
228	Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry. <i>Blood</i> , 2016, 128, 2815-2815.	0.6	1
229	Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. <i>Blood</i> , 2015, 125, 133-139.	0.6	86
230	Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic CD8^+ T cells against immunogenic leukemia-associated antigens. <i>International Journal of Cancer</i> , 2015, 137, 2083-2092.	2.3	19
231	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e122-e124.	1.7	20
232	International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with \geq 30% blasts. <i>Blood</i> , 2015, 126, 291-299.	0.6	982
233	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. <i>Haematologica</i> , 2015, 100, 324-330.	1.7	86
234	MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. <i>Experimental Hematology</i> , 2015, 43, 858-868.e7.	0.2	28

#	ARTICLE	IF	CITATIONS
235	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. <i>British Journal of Haematology</i> , 2015, 169, 694-700.	1.2	90
236	Mutations driving CLL and their evolution in progression and relapse. <i>Nature</i> , 2015, 526, 525-530.	13.7	868
237	Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1136-1152.	13.9	2,466
238	Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). <i>Haematologica</i> , 2015, 100, 1451-1459.	1.7	34
239	Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF- κ B and STAT6. <i>International Journal of Cancer</i> , 2015, 136, 65-73.	2.3	11
240	Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 1381-1381.	0.6	1
241	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3A _{mut}) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2015, 126, 226-226.	0.6	4
242	Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2436-2436.	0.6	1
243	Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive AML Patients within the AMLSG 16-10 Trial: A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2015, 126, 2585-2585.	0.6	6
244	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2586-2586.	0.6	1
245	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). <i>Blood</i> , 2015, 126, 322-322.	0.6	32
246	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3744-3744.	0.6	7
247	The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 3754-3754.	0.6	2
248	Long-Term Interferon- α Treatment in Essential Thrombocythemia. <i>Blood</i> , 2015, 126, 4064-4064.	0.6	4
249	A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis. <i>Blood</i> , 2015, 126, 826-826.	0.6	9
250	Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data. <i>Blood</i> , 2015, 126, 85-85.	0.6	1
251	The Homeobox Gene VENTX Collaborates with AML1-ETO in Inducing an Acute Leukemia in Mice. <i>Blood</i> , 2015, 126, 3642-3642.	0.6	0
252	Sequential Molecular Characterization Based Delineation of Potential Driver Aberrations in ACUTE Myeloid Leukemia Following Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 4123-4123.	0.6	0

#	ARTICLE	IF	CITATIONS
253	EÅµ-TCL1mTerc -/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1724-1724.	0.6	0
254	Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis. Blood, 2015, 126, 224-224.	0.6	0
255	The Role of microRNA-155 in Mouse Models of MLL -AML. Blood, 2015, 126, 2446-2446.	0.6	0
256	The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia. Blood, 2015, 126, 1244-1244.	0.6	0
257	Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA. Blood, 2015, 126, 1581-1581.	0.6	0
258	A Tumor Suppressor microRNA Defines the Leukemic Hierarchy in Acute Myeloid Leukemia. Blood, 2015, 126, 3653-3653.	0.6	0
259	Mutational Landscape of Del(9q) Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3844-3844.	0.6	0
260	Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome. Blood, 2015, 126, 5523-5523.	0.6	0
261	Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG). Blood, 2015, 126, 227-227.	0.6	0
262	Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group. Blood, 2015, 126, 3941-3941.	0.6	0
263	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. Blood, 2015, 126, 5263-5263.	0.6	0
264	Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica, 2014, 99, 308-313.	1.7	32
265	Poor efficacy and tolerability of <sc>Râ€CHOP</sc> in relapsed/refractory chronic lymphocytic leukemia and <sc>R</sc>ichter transformation. American Journal of Hematology, 2014, 89, E239-43.	2.0	81
266	Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy. Oncology Reports, 2014, 31, 384-390.	1.2	19
267	Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2014, 370, 1101-1110.	13.9	1,284
268	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood, 2014, 124, 49-62.	0.6	244
269	Inactivating CUX1 mutations promote tumorigenesis. Nature Genetics, 2014, 46, 33-38.	9.4	111
270	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood, 2014, 123, 914-920.	0.6	167

#	ARTICLE	IF	CITATIONS
271	Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2014, 4, 362-375.	7.7	561
272	A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia. <i>Cell</i> , 2014, 157, 369-381.	13.5	571
273	Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2014, 4, 348-361.	7.7	135
274	Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. <i>Haematologica</i> , 2014, 99, 1095-1100.	1.7	101
275	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. <i>Haematologica</i> , 2014, 99, 1285-1291.	1.7	2
276	Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. <i>Haematologica</i> , 2014, 99, e133-e135.	1.7	11
277	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. <i>Blood</i> , 2014, 123, 3247-3254.	0.6	428
278	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 420-425.	0.6	14
279	Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. <i>Blood</i> , 2014, 123, 4027-4036.	0.6	72
280	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. <i>Blood</i> , 2014, 124, 1426-1433.	0.6	204
281	Differential impact of allelic ratio and insertion site in FLT3-ITD“positive AML with respect to allogeneic transplantation. <i>Blood</i> , 2014, 124, 3441-3449.	0.6	350
282	Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial. <i>Blood</i> , 2014, 124, 10-10.	0.6	11
283	Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia “ Updated Results of the Italian-German APL0406 Trial on the Extended Final Series. <i>Blood</i> , 2014, 124, 12-12.	0.6	5
284	Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). <i>Blood</i> , 2014, 124, 19-19.	0.6	62
285	Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in “œltra High-risk“CLL: Final Results from the CLL20 Phase II Study. <i>Blood</i> , 2014, 124, 1991-1991.	0.6	11
286	Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911). <i>Blood</i> , 2014, 124, 1992-1992.	0.6	4
287	The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia. <i>Blood</i> , 2014, 124, 387-387.	0.6	36
288	Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2014, 124, 4699-4699.	0.6	2

#	ARTICLE	IF	CITATIONS
289	Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study. <i>Blood</i> , 2014, 124, 621-621.	0.6	8
290	Survival Analysis in Patients with Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation, a Single Center Study (1994-2013). <i>Blood</i> , 2014, 124, 1233-1233.	0.6	0
291	A Multicenter Phase-Ib/II Study of Ruxolitinib/Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis: Safety Data from the MpnsG-0212 Trial (NCT01644110). <i>Blood</i> , 2014, 124, 3161-3161.	0.6	1
292	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). <i>Blood</i> , 2014, 124, 1254-1254.	0.6	0
293	The Adhesion Molecule α 6 β 1-Integrin Cooperates with the Homeobox Gene Hoxa9 to Induce Acute Myeloid Leukemia in Mice. <i>Blood</i> , 2014, 124, 2217-2217.	0.6	0
294	High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?. <i>Blood</i> , 2014, 124, 1964-1964.	0.6	0
295	Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts \leq 10G/L. <i>Blood</i> , 2014, 124, 2636-2636.	0.6	0
296	Defects in the RAS/RTK Signaling Pathways Predominate the Mutational Spectrum of EVI1/GATA2 Rearranged Myeloid Malignancies with Inv(3)t(3;3). <i>Blood</i> , 2014, 124, 701-701.	0.6	0
297	High Resolution Genomic Profiling of Primary α 6 β 1-Integrin and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. <i>Blood</i> , 2014, 124, 3288-3288.	0.6	0
298	Hoxa9/Meis1 Mediate Leukemic Programming through MicroRNA-155. <i>Blood</i> , 2014, 124, 884-884.	0.6	0
299	Cytotoxic T-Cell Responses (CTL) Against Several Leukemia-Associated-Antigens (LAA) Related to the Detected Cytokine Profile in the Course of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Donor Lymphocyte Infusion (DLI) in Patients with Different Hematological Diseases. <i>Blood</i> , 2014, 124, 2442-2442.	0.6	4
300	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	13.9	1,284
301	Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. <i>Molecular Cancer</i> , 2013, 12, 46.	7.9	48
302	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). <i>Blood</i> , 2013, 121, 4769-4777.	0.6	162
303	Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. <i>Blood</i> , 2013, 122, 100-108.	0.6	242
304	Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. <i>Blood</i> , 2013, 121, 2503-2511.	0.6	41
305	Epigenetic Upregulation of lncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF- κ B. <i>PLoS Genetics</i> , 2013, 9, e1003373.	1.5	134
306	Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. <i>Cancer</i> , 2013, 119, 2258-2267.	2.0	56

#	ARTICLE	IF	CITATIONS
307	Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia. Hematology American Society of Hematology Education Program, 2013, 2013, 324-330.	0.9	46
308	Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leukemia and Lymphoma, 2013, 54, 1821-1822.	0.6	26
309	Deregulated Expression of <i>EVI1</i> Defines a Poor Prognostic Subset of <i>MLL</i> -Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. Journal of Clinical Oncology, 2013, 31, 95-103.	0.8	95
310	T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/ATREC ratio and thymic naive T cells. Haematologica, 2013, 98, 1600-1608.	1.7	55
311	Donor Lymphocyte Infusion Induces Polyspecific CD8 ⁺ T-Cell Responses With Concurrent Molecular Remission in Acute Myeloid Leukemia With <i>NPM1</i> Mutation. Journal of Clinical Oncology, 2013, 31, e44-e47.	0.8	40
312	A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the <i>Bcr</i> -like kinase inhibitor <i>Bcr</i> 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. British Journal of Haematology, 2013, 163, 214-222.	1.2	36
313	<i>BRAF</i> mutations in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1177-1182.	0.6	45
314	PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17). Clinical Cancer Research, 2013, 19, 2562-2571.	3.2	32
315	Circulating microRNAs in hematological diseases: principles, challenges, and perspectives. Blood, 2013, 121, 4977-4984.	0.6	118
316	Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSC). Blood, 2013, 121, 170-177.	0.6	164
317	Telomere length in mantle cell lymphoma. Blood, 2013, 121, 1184-1187.	0.6	19
318	TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood, 2013, 121, 3284-3288.	0.6	96
319	Immune responses against the mutated region of cytoplasmatic <i>NPM1</i> might contribute to the favorable clinical outcome of AML patients with <i>NPM1</i> mutations (<i>NPM1</i> mut). Blood, 2013, 122, 1087-1088.	0.6	61
320	The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant <i>CEBPA</i> . Blood, 2013, 122, 1576-1582.	0.6	138
321	<i>FLT3</i> Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors. PLoS ONE, 2013, 8, e53190.	1.1	87
322	Progranulin Is a Novel Independent Predictor of Disease Progression and Overall Survival in Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e72107.	1.1	26
323	<i>CDX2</i> -driven leukemogenesis involves <i>KLF4</i> repression and deregulated <i>PPARγ3</i> signaling. Journal of Clinical Investigation, 2013, 123, 299-314.	3.9	47
324	Decitabine Response Associated Gene Expression Patterns In Acute Myeloid Leukemia (AML). Blood, 2013, 122, 3756-3756.	0.6	7

#	ARTICLE	IF	CITATIONS
325	Molecular Characterization Of Myelofibrosis Patients With Cytopenia Treated With Pomalidomide: Results From The Mpnsg 01-09 Study. Blood, 2013, 122, 4064-4064.	0.6	1
326	Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG). Blood, 2013, 122, 4127-4127.	0.6	5
327	Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia â€œ First Results Of a Randomized German-French Cooperative Phase III Trial. Blood, 2013, 122, 524-524.	0.6	32
328	Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG). Blood, 2013, 122, 526-526.	0.6	40
329	NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). Blood, 2013, 122, 527-527.	0.6	9
330	Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. Blood, 2013, 122, 6-6.	0.6	21
331	Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial. Blood, 2013, 122, 671-671.	0.6	3
332	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. Blood, 2013, 122, 2555-2555.	0.6	0
333	Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia. Blood, 2013, 122, 830-830.	0.6	0
334	Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). Blood, 2013, 122, 3878-3878.	0.6	0
335	Differential DNA Methylation Predicts Response To Combined Treatment Regimens With a DNA Methyltransferase Inhibitor In Acute Myeloid Leukemia (AML). Blood, 2013, 122, 2539-2539.	0.6	35
336	Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 1626-1626.	0.6	0
337	An Adapted Gating Strategy Integrating a Myelomonocytic Window Is Necessary For Correct Flow Cytometric Diagnosis In a Large Proportion Of AML With Mutated NPM1. Blood, 2013, 122, 2593-2593.	0.6	0
338	Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG). Blood, 2013, 122, 1332-1332.	0.6	0
339	ADARB1 Is Involved In a Reduced Maturation Of The miR15a/Mir-16-1 Family In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 1252-1252.	0.6	1
340	The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia. Blood, 2013, 122, 1314-1314.	0.6	0
341	Pomalidomide In MPNâ€œ-associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study. Blood, 2013, 122, 2822-2822.	0.6	0
342	Prospective Phase III Trial Of Valproic Acid (VPA) In Combination With All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy For AML In Older Patients: Final and Molecular Subset Analyses Of The AMLSG 06-04 Study. Blood, 2013, 122, 3927-3927.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6668-6673.	3.3	23
344	Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. Journal of Experimental Medicine, 2012, 209, 697-711.	4.2	63
345	Targeted therapies through microRNAs: pulp or fiction?. Therapeutic Advances in Hematology, 2012, 3, 97-104.	1.1	10
346	A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica, 2012, 97, 393-401.	1.7	219
347	Raising hematology's European voice: the importance of calling yourself a hematologist. Haematologica, 2012, 97, 476-478.	1.7	2
348	Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. Blood, 2012, 120, 1282-1289.	0.6	129
349	Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood, 2012, 119, 551-558.	0.6	140
350	Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Blood, 2012, 119, 4851-4859.	0.6	27
351	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. Blood, 2012, 119, e67-e75.	0.6	66
352	High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood, 2012, 120, 2118-2126.	0.6	62
353	Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet, The, 2012, 379, 1791-1799.	6.3	564
354	Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood, 2012, 119, 4101-4107.	0.6	107
355	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell, 2012, 22, 683-697.	7.7	213
356	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. Cell, 2012, 148, 59-71.	13.5	743
357	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood, 2012, 120, e83-e92.	0.6	131
358	Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm – Combined Prospective Analysis by the German AML Intergroup. Journal of Clinical Oncology, 2012, 30, 3604-3610.	0.8	121
359	Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial. Journal of Clinical Oncology, 2012, 30, 980-988.	0.8	397
360	EV1 is critical for the pathogenesis of a subset of MLL-AF9 rearranged AMLs. Blood, 2012, 119, 5838-5849.	0.6	76

#	ARTICLE	IF	CITATIONS
361	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. <i>Blood</i> , 2012, 119, 2114-2121.	0.6	553
362	miRNA-130a Targets <i>ATG2B</i> and <i>DICER1</i> to Inhibit Autophagy and Trigger Killing of Chronic Lymphocytic Leukemia Cells. <i>Cancer Research</i> , 2012, 72, 1763-1772.	0.4	185
363	Quantitative analyses of <i>DAPK1</i> methylation in AML and MDS. <i>International Journal of Cancer</i> , 2012, 131, E138-42.	2.3	34
364	Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3209-3216.	0.8	388
365	<i>TET2</i> Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 1350-1357.	0.8	198
366	Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 2483-2491.	0.8	120
367	Prognostic significance of serum cystatin C in multiple myeloma. <i>International Journal of Hematology</i> , 2012, 95, 545-550.	0.7	21
368	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. <i>Blood</i> , 2012, 120, 6-6.	0.6	18
369	Effect of epitopes derived from the mutated region of cytoplasmic nucleophosmine 1 (NPM1) on CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 6567-6567.	0.8	0
370	<i>RUNX1</i> Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 1364-1372.	0.8	349
371	Impact of Genetic Features on Treatment Decisions in AML. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 36-42.	0.9	60
372	4.13 Proposal of a New Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on an Overall Survival Analysis of Three German CLL Study Group Phase III Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S225-S227.	0.2	2
373	4.23 MDM2 Promotor Polymorphism and Disease Characteristics in CLL: Individual Patient Data Meta-Analysis of 2598 CLL Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S233-S235.	0.2	0
374	DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. <i>Blood</i> , 2011, 117, 1622-1632.	0.6	35
375	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. <i>Blood</i> , 2011, 117, 2469-2475.	0.6	341
376	Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1783-1791.	1.7	39
377	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. <i>Blood</i> , 2011, 117, 2137-2145.	0.6	392
378	The European LeukemiaNet: achievements and perspectives. <i>Haematologica</i> , 2011, 96, 156-162.	1.7	15

#	ARTICLE	IF	CITATIONS
379	Nurse-like cells show deregulated expression of genes involved in immunocompetence. <i>British Journal of Haematology</i> , 2011, 154, 349-356.	1.2	32
380	Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. <i>Journal of Clinical Oncology</i> , 2011, 29, 475-486.	0.8	510
381	Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 51-58.	1.5	6
382	Importance of genetics in chronic lymphocytic leukemia. <i>Blood Reviews</i> , 2011, 25, 131-137.	2.8	75
383	Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias. <i>Cancer Research</i> , 2011, 71, 4117-4129.	0.4	55
384	Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 2709-2716.	0.8	355
385	Prognostic Importance of Histone Methyltransferase MLL5 Expression in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 682-689.	0.8	53
386	A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itid Positive Acute Myeloid Leukemia: Updated Interim Results. <i>Blood</i> , 2011, 118, 2576-2576.	0.6	12
387	Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 4997-4997.	0.6	1
388	Role of Microenvironment-Associated Chemokines and Cytokines for Binet Stage A CLL Patients Included in a Prospective Trial (CLL1 trial) of the German CLL Study Group (GCLLSG): sll2Ralpha Is An Independent Predictor of Progression-Free Survival (PFS). <i>Blood</i> , 2011, 118, 3869-3869.	0.6	0
389	Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk. <i>Haematologica</i> , 2010, 95, 1880-1888.	1.7	5
390	Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. <i>Haematologica</i> , 2010, 95, 102-109.	1.7	31
391	Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2010, 95, 1969-1972.	1.7	18
392	High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. <i>Haematologica</i> , 2010, 95, 1191-1197.	1.7	124
393	High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations. <i>Haematologica</i> , 2010, 95, 666-669.	1.7	44
394	Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. <i>Blood</i> , 2010, 115, 636-642.	0.6	137
395	Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. <i>Blood</i> , 2010, 115, 2586-2591.	0.6	131
396	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.	0.6	2,963

#	ARTICLE	IF	CITATIONS
397	Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. <i>Experimental Hematology</i> , 2010, 38, 1126-1130.	0.2	129
398	Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at <i>PML</i> and <i>RARA</i> loci. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 726-732.	1.5	32
399	High-throughput detection of nuclear factor- κ B activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay. <i>International Journal of Cancer</i> , 2010, 127, 404-411.	2.3	25
400	Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. <i>British Journal of Haematology</i> , 2010, 148, 948-950.	1.2	55
401	<i>KIT</i> mutations confer a distinct gene expression signature in core binding factor leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 925-937.	1.2	44
402	<i>SYK</i> carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL). <i>British Journal of Haematology</i> , 2010, 150, 633-636.	1.2	12
403	From pathogenesis to treatment of chronic lymphocytic leukaemia. <i>Nature Reviews Cancer</i> , 2010, 10, 37-50.	12.8	503
404	Prognostic Impact of Minimal Residual Disease in <i>CBFB-MYH11</i> "Positive Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3724-3729.	0.8	126
405	High <i>EVI1</i> Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities. <i>Journal of Clinical Oncology</i> , 2010, 28, 2101-2107.	0.8	222
406	<i>IDH1</i> and <i>IDH2</i> Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With <i>NPM1</i> Mutation Without <i>FLT3</i> Internal Tandem Duplication. <i>Journal of Clinical Oncology</i> , 2010, 28, 3636-3643.	0.8	728
407	Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4199-4206.	0.8	397
408	Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A. <i>Journal of Clinical Oncology</i> , 2010, 28, 4642-4648.	0.8	205
409	Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 71-84.	0.7	55
410	<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 4473-4479.	0.8	523
411	Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. <i>Blood</i> , 2010, 116, 2438-2447.	0.6	273
412	Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3890-3898.	0.8	217
413	Mir-223 Is Dispensable for the Onset of Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 501-501.	0.6	2
414	Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSC). <i>Blood</i> , 2010, 116, 918-918.	0.6	2

#	ARTICLE	IF	CITATIONS
415	Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup. <i>Blood</i> , 2010, 116, 2175-2175.	0.6	0
416	Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 1914-1914.	0.6	0
417	BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 1837-1842.	0.6	12
418	miR-34a as part of the resistance network in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 3801-3808.	0.6	258
419	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 2349.	3.8	758
420	A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2009, 69, 8977-8986.	0.4	55
421	High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2009, 361, 1235-1248.	13.9	745
422	Danish CLLâ€‘Study revisited: FISH on a cohort with a 20â€‘yr followâ€‘up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2009, 83, 156-158.	1.1	6
423	Microarrayâ€‘based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 39-54.	1.5	70
424	Dasatinib inhibits the proliferation and function of CD4⁺CD25⁺ regulatory T cells. <i>British Journal of Haematology</i> , 2009, 144, 195-205.	1.2	64
425	Treatment resistance in chronic lymphocytic leukemiaâ€‘the role of the p53 pathway. <i>Leukemia and Lymphoma</i> , 2009, 50, 510-513.	0.6	35
426	Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 3994-4001.	0.8	257
427	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2009, 113, 1875-1891.	0.6	856
428	Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. <i>Haematologica</i> , 2009, 94, 54-60.	1.7	195
429	Impaired function of primitive hematopoietic cells in mice lacking the Mixed-Lineage-Leukemia homolog Mll5. <i>Blood</i> , 2009, 113, 1444-1454.	0.6	84
430	Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. <i>Blood</i> , 2009, 113, 4505-4511.	0.6	164
431	Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. <i>Blood</i> , 2009, 114, 2386-2392.	0.6	242
432	Identification and Characterization of Peptide Ligands for Stereotyped Subset and Non-Subset B-Cell Receptors of Patients with M- and U-CLL. <i>Blood</i> , 2009, 114, 4369-4369.	0.6	2

#	ARTICLE	IF	CITATIONS
433	SNP-Array Profiling Identifies Complex Aberrations and Candidate Genes in Myeloproliferative Neoplasms with Leukemic Transformation.. Blood, 2009, 114, 2608-2608.	0.6	0
434	Genome-Wide Analysis of Alternative Splicing Points to Novel Leukemia Relevant Genes in Acute Myeloid Leukemia.. Blood, 2009, 114, 2391-2391.	0.6	0
435	Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Experimental Hematology, 2008, 36, 1297-1308.	0.2	77
436	Chromosomal Abnormalities in Cancer. New England Journal of Medicine, 2008, 359, 722-734.	13.9	188
437	First Demonstration of Leukemia Imaging with the Proliferation Marker ¹⁸ F-Fluorodeoxythymidine. Journal of Nuclear Medicine, 2008, 49, 1756-1762.	2.8	68
438	Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. New England Journal of Medicine, 2008, 358, 1909-1918.	13.9	1,514
439	HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR. Biology of Blood and Marrow Transplantation, 2008, 14, 187-196.	2.0	51
440	Molecular diagnostics in chronic lymphocytic leukemia – Pathogenetic and clinical implications. Leukemia and Lymphoma, 2008, 49, 864-873.	0.6	37
441	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood, 2008, 111, 5446-5456.	0.6	2,887
442	Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood, 2008, 112, 3322-3329.	0.6	348
443	Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells: Fig. 1.. Clinical Cancer Research, 2008, 14, 7161-7166.	3.2	89
444	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica, 2008, 93, 1219-1226.	1.7	23
445	Molecular characterization of acute myeloid leukemia. Haematologica, 2008, 93, 976-982.	1.7	143
446	Multimer Staining of Cytomegalovirus Phosphoprotein 65 – Specific T Cells for Diagnosis and Therapeutic Purposes: A Comparative Study. Clinical Infectious Diseases, 2008, 46, e96-e105.	2.9	42
447	The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica, 2008, 93, 1111-1113.	1.7	34
448	Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway. Cell Cycle, 2008, 7, 3810-3814.	1.3	72
449	Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica, 2008, 93, 826-833.	1.7	64
450	Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood, 2008, 111, 2246-2252.	0.6	122

#	ARTICLE	IF	CITATIONS
451	An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. <i>Blood</i> , 2008, 111, 4490-4495.	0.6	94
452	Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. <i>Haematologica</i> , 2008, 93, 680-687.	1.7	41
453	Induction of Apoptosis in CLL by Peptides Binding the B-Cell Antigen Receptor in Vitro. <i>Blood</i> , 2008, 112, 3151-3151.	0.6	1
454	Gene Expression Profiling in AML with Normal Karyotype: A Multicenter Study Investigating Molecular Markers in 252 Cases. <i>Blood</i> , 2008, 112, 751-751.	0.6	1
455	High-Resolution SNP-Array Profiling Discloses Novel Genomic Aberrations in BCR/ABL-Negative Myeloproliferative Neoplasms with Myelofibrosis. <i>Blood</i> , 2008, 112, 2794-2794.	0.6	0
456	Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML. <i>Blood</i> , 2008, 112, 1487-1487.	0.6	0
457	Distinct Expression Patterns in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Characterized by Uniparental Disomy. <i>Blood</i> , 2008, 112, 1193-1193.	0.6	0
458	Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients. <i>Blood</i> , 2008, 112, 2641-2641.	0.6	3
459	Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial. <i>Blood</i> , 2008, 112, 2973-2973.	0.6	8
460	Common Self-Renewal Pathways Contribute to the Induction of Acute Myeloid Leukemias Associated with Different Oncogenes. <i>Blood</i> , 2008, 112, 505-505.	0.6	0
461	Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors. <i>Journal of Clinical Oncology</i> , 2007, 25, 2770-2777.	0.8	54
462	Implication of the Molecular Characterization of Acute Myeloid Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 412-419.	0.9	41
463	Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. <i>Haematologica</i> , 2007, 92, 1242-1245.	1.7	195
464	Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. <i>Haematologica</i> , 2007, 92, 763-770.	1.7	44
465	Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. <i>Current Opinion in Hematology</i> , 2007, 14, 106-114.	1.2	66
466	Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 439-453.	0.7	61
467	Overexpression of the paternally expressed gene <i>PEG10</i> from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2007, 121, 1984-1993.	2.3	67
468	Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse. <i>British Journal of Haematology</i> , 2007, 136, 127-130.	1.2	12

#	ARTICLE	IF	CITATIONS
469	Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2007, 137, 297-306.	1.2	37
470	Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. <i>Cancer Cell</i> , 2007, 12, 501-513.	7.7	174
471	Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 849-861.	2.0	24
472	The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. <i>Journal of Clinical Investigation</i> , 2007, 117, 1037-1048.	3.9	127
473	Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.. <i>Blood</i> , 2007, 110, 1806-1806.	0.6	9
474	p53 Inactivation in CLL: Pattern of 110 TP53 Mutations.. <i>Blood</i> , 2007, 110, 2064-2064.	0.6	3
475	Combined Analysis of Valproic Acid Induced MicroRNA and Gene Expression Changes in Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 869-869.	0.6	1
476	Prognostic Impact of BAALC Expression in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 3485-3485.	0.6	0
477	Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF- κ B Pathway.. <i>Blood</i> , 2007, 110, 2368-2368.	0.6	1
478	Streptamer Technology for the Assessment of CMVpp65 Specific CD8+ T Cell Frequencies and for the Adoptive T Cell Transfer to Post-Transplant Patients.. <i>Blood</i> , 2007, 110, 1964-1964.	0.6	0
479	The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutic Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.. <i>Blood</i> , 2007, 110, 2051-2051.	0.6	0
480	KIT Mutations Define Characteristic Gene Expression Signatures in Core Binding Factor Leukemias.. <i>Blood</i> , 2007, 110, 3163-3163.	0.6	0
481	Acute myeloid leukaemia. <i>Lancet, The</i> , 2006, 368, 1894-1907.	6.3	1,103
482	Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. <i>Blood</i> , 2006, 107, 2889-2894.	0.6	167
483	Disclosure of Candidate Genes in Acute Myeloid Leukemia With Complex Karyotypes Using Microarray-Based Molecular Characterization. <i>Journal of Clinical Oncology</i> , 2006, 24, 3887-3894.	0.8	141
484	Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. <i>Blood</i> , 2006, 107, 2090-2093.	0.6	54
485	V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. <i>Blood</i> , 2006, 107, 2098-2100.	0.6	194
486	Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. <i>Blood</i> , 2006, 107, 1242-1243.	0.6	59

#	ARTICLE	IF	CITATIONS
487	Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. <i>Blood</i> , 2006, 108, 3280-3288.	0.6	269
488	Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. <i>Experimental Hematology</i> , 2006, 34, 1709-1719.	0.2	41
489	Risk Stratification in Chronic Lymphocytic Leukemia. <i>Seminars in Oncology</i> , 2006, 33, 186-194.	0.8	67
490	Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. <i>International Journal of Cancer</i> , 2006, 118, 1831-1835.	2.3	43
491	Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7741-7746.	3.3	54
492	Molecular Imaging of Proliferation in Malignant Lymphoma. <i>Cancer Research</i> , 2006, 66, 11055-11061.	0.4	173
493	Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, 969-975.	0.8	177
494	Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphoma. <i>FASEB Journal</i> , 2006, 20, 1188-1190.	0.2	21
495	Characterization of NPM1-Mutated/FLT3 ITD-Negative Acute Myeloid Leukemia with Normal Karyotype by Gene Expression Profiling.. <i>Blood</i> , 2006, 108, 155-155.	0.6	2
496	Prognosis of Adult Patients ≥60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup.. <i>Blood</i> , 2006, 108, 16-16.	0.6	2
497	Impact of Pegfilgrastim on Hematological Reconstitution and Incidence of Neutropenic Fever after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukemia: Comparative Analysis between AMLSG 07-04 and the German AML Intergroup Trial.. <i>Blood</i> , 2006, 108, 2020-2020.	0.6	67
498	Gene Mutations as Predictive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.. <i>Blood</i> , 2006, 108, 4-4.	0.6	12
499	A FLT3 Gene-Expression Signature Outperforms FLT3 Status in Predicting Clinical Outcome for Patients with Normal Karyotype AML.. <i>Blood</i> , 2006, 108, 2311-2311.	0.6	0
500	Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells.. <i>Blood</i> , 2006, 108, 5471-5471.	0.6	0
501	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. <i>Blood</i> , 2006, 108, 1949-1949.	0.6	1
502	RHAMM/CD168 Is a Novel Leukemia Associated Antigen with Prognostic Value for Patients with B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006, 108, 2773-2773.	0.6	0
503	Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.. <i>Blood</i> , 2006, 108, 2201-2201.	0.6	0
504	Identification of High-Level DNA Amplifications in AML with Complex Karyotype Using Array-CGH.. <i>Blood</i> , 2006, 108, 1914-1914.	0.6	0

#	ARTICLE	IF	CITATIONS
505	RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits Immunological and Clinical Responses.. Blood, 2006, 108, 409-409.	0.6	0
506	Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.. Blood, 2006, 108, 414-414.	0.6	0
507	In Vitro and In Vivo Monitoring of Valproic Acid Effects on Gene Expression Signatures in Adult Acute Myeloid Leukemia.. Blood, 2006, 108, 2605-2605.	0.6	0
508	Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. Journal of Nuclear Medicine, 2006, 47, 278-86.	2.8	16
509	Cancer vaccines for patients with acute myeloid leukemia—definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica, 2006, 91, 1653-61.	1.7	70
510	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 2005, 105, 986-993.	0.6	481
511	Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 2005, 106, 3740-3746.	0.6	779
512	188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. British Journal of Haematology, 2005, 130, 604-613.	1.2	92
513	Duplication of chromosome arms 9q and 11q: Evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma. Genes Chromosomes and Cancer, 2005, 42, 78-81.	1.5	5
514	Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes. Genes Chromosomes and Cancer, 2005, 42, 128-143.	1.5	34
515	Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosomes and Cancer, 2005, 42, 427-432.	1.5	36
516	Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunology, Immunotherapy, 2005, 54, 685-693.	2.0	56
517	Evidence for Distinct Pathomechanisms in Genetic Subgroups of Chronic Lymphocytic Leukemia Revealed by Quantitative Expression Analysis of Cell Cycle, Activation, and Apoptosis-Associated Genes. Journal of Clinical Oncology, 2005, 23, 3780-3792.	0.8	66
518	Impact of Fluoroquinolone Prophylaxis on Reduced Infection-Related Mortality among Patients with Neutropenia and Hematologic Malignancies. Clinical Infectious Diseases, 2005, 40, 1087-1093.	2.9	116
519	Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 2005, 107, 885-891.	0.6	524
520	Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood, 2005, 107, 859-861.	0.6	140
521	Prognostic Gene-Expression Signatures in Adult Acute Myeloid Leukemia with Normal Karyotype.. Blood, 2005, 106, 756-756.	0.6	38
522	Array-CGH and Gene Expression Profiling Based Molecular Characterization of Myeloid Leukemia Cell Lines.. Blood, 2005, 106, 4397-4397.	0.6	20

#	ARTICLE	IF	CITATIONS
523	Strikingly Homologous Immunoglobulin Gene Rearrangements and Poor Outcome in VH3-21-Utilizing Chronic Lymphocytic Leukemia Independent of Geographical Origin and Mutational Status.. Blood, 2005, 106, 175-175.	0.6	6
524	Gene Expression Profiling Identifies Distinct Subclasses in Core Binding Factor Acute Myeloid Leukemia.. Blood, 2005, 106, 673-673.	0.6	7
525	CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica, 2005, 90, 489-93.	1.7	43
526	The use of molecular markers in selecting therapy for CLL. Clinical Advances in Hematology and Oncology, 2005, 3, 103-4.	0.3	2
527	Disruption of C/EBP β Function in Acute Myeloid Leukemia. New England Journal of Medicine, 2004, 351, 2370-2372.	13.9	25
528	Microarray Gene Expression Profiling of B-Cell Chronic Lymphocytic Leukemia Subgroups Defined by Genomic Aberrations and VH Mutation Status. Journal of Clinical Oncology, 2004, 22, 3937-3949.	0.8	200
529	Genomic DNA-Chip Hybridization Reveals a Higher Incidence of Genomic Amplifications in Pancreatic Cancer than Conventional Comparative Genomic Hybridization and Leads to the Identification of Novel Candidate Genes. Cancer Research, 2004, 64, 4428-4433.	0.4	140
530	Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1039-1044.	3.3	221
531	CD34+ cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. British Journal of Haematology, 2004, 126, 527-535.	1.2	28
532	mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. International Journal of Cancer, 2004, 108, 704-711.	2.3	118
533	Cross-trial networking in AML: a step forward rather than corner cutting. Leukemia Research, 2004, 28, 649-650.	0.4	3
534	CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations. Journal of Clinical Oncology, 2004, 22, 624-633.	0.8	427
535	Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia. New England Journal of Medicine, 2004, 350, 1605-1616.	13.9	915
536	The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood, 2004, 103, 2850-2858.	0.6	101
537	Treatment with Pegylated Interferon β (PegIntron) for High-Risk Essential Thrombocythemia: Results of a Phase II Study.. Blood, 2004, 104, 1522-1522.	0.6	3
538	Dendritic Cells (DC) Generated from AML Blasts Express Leukemia Associated Antigens Eliciting Specific Cytotoxic T Cell Responses in the Autologous Host after DC Vaccination.. Blood, 2004, 104, 1812-1812.	0.6	4
539	Reversal of Acquired von Willebrand Disease after Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with High Risk Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 4014-4014.	0.6	1
540	Drug-Response Signature Predicts Outcome in Adult Acute Myeloid Leukemia and Associates Poor Response with Molecular Characteristics of Hematopoietic Stem Cells.. Blood, 2004, 104, 2024-2024.	0.6	0

#	ARTICLE	IF	CITATIONS
541	Prognostic Relevance of Lipoprotein Lipase (LPL) Expression in B-CLL.. Blood, 2004, 104, 177-177.	0.6	0
542	Identification of Distinct inv(16) Subclasses in Adult Acute Myeloid Leukemia Based on Gene Expression Profiling.. Blood, 2004, 104, 2037-2037.	0.6	0
543	Characterization of T Cell Epitopes of the Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) in Acute Myeloid Leukemia.. Blood, 2004, 104, 2540-2540.	0.6	2
544	Identification of Genomic Imbalances in AML with Complex Karyotype Using Matrix-Based Comparative Genomic Hybridization.. Blood, 2004, 104, 3382-3382.	0.6	0
545	Cytogenetic evolution of follicular lymphoma. Seminars in Cancer Biology, 2003, 13, 183-190.	4.3	32
546	Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. International Journal of Cancer, 2003, 106, 224-231.	2.3	84
547	Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. British Journal of Haematology, 2003, 120, 1000-1008.	1.2	36
548	Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. British Journal of Haematology, 2003, 122, 193-201.	1.2	38
549	Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization. Oncogene, 2003, 22, 1425-1429.	2.6	99
550	Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. Genes Chromosomes and Cancer, 2003, 38, 274-280.	1.5	26
551	Human Chromosome 7: DNA Sequence and Biology. Science, 2003, 300, 767-772.	6.0	185
552	Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor Leukemias. Journal of Clinical Oncology, 2003, 21, 4413-4422.	0.8	120
553	Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood, 2003, 101, 2049-2053.	0.6	116
554	VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood, 2003, 102, 3003-3009.	0.6	136
555	Comparison of Cytogenetic and Molecular Cytogenetic Detection of Chromosome Abnormalities in 240 Consecutive Adult Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2002, 20, 2480-2485.	0.8	98
556	Myeloablative Radioimmunotherapy with Re-188-anti-CD66-Antibody for Conditioning of High-Risk Leukemia Patients Prior to Stem Cell Transplantation: Biodistribution, Biokinetics and Immediate Toxicities. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 151-163.	0.7	38
557	Clinicopathologic Correlations of Genomic Gains and Losses in Follicular Lymphoma. Journal of Clinical Oncology, 2002, 20, 4523-4530.	0.8	79
558	Campath-1Hä€“Induced Complete Remission of Chronic Lymphocytic Leukemia despite p53 Gene Mutation and Resistance to Chemotherapy. New England Journal of Medicine, 2002, 347, 452-453.	13.9	195

#	ARTICLE	IF	CITATIONS
559	Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF- κ B/Rel ϵ regulated inhibitors of apoptosis. <i>Blood</i> , 2002, 100, 3749-3756.	0.6	79
560	Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002, 99, 4116-4121.	0.6	91
561	Pathogenic complexity of gastric B-cell lymphoma. <i>Blood</i> , 2002, 100, 1095-1097.	0.6	8
562	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. <i>Blood</i> , 2002, 100, 4372-4380.	0.6	794
563	Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia Study Group Ulm. <i>Journal of Clinical Oncology</i> , 2002, 20, 3254-3261.	0.8	291
564	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. <i>Blood</i> , 2002, 99, 4554-4561.	0.6	125
565	Receptor for hyaluronan acid mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. <i>Experimental Hematology</i> , 2002, 30, 1029-1035.	0.2	126
566	Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies. <i>Leukemia Research</i> , 2002, 26, 1073-1075.	0.4	13
567	Automated Screening for Genomic Imbalances using Matrix-Based Comparative Genomic Hybridization. <i>Laboratory Investigation</i> , 2002, 82, 47-60.	1.7	96
568	V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 1410-6.	0.6	206
569	Molecular Aspects of B-Cell Lymphomas of the Gastrointestinal Tract. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 57-64.	2.1	6
570	Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 807-815.	2.2	36
571	Mutation analysis of the origin recognition complex subunit 5 (ORC5L) gene in adult patients with myeloid leukemias exhibiting deletions of chromosome band 7q22. <i>Human Genetics</i> , 2001, 108, 304-309.	1.8	8
572	Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. <i>British Journal of Haematology</i> , 2001, 114, 342-348.	1.2	108
573	Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2001, 91, 180-186.	2.3	72
574	CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. <i>International Journal of Cancer</i> , 2001, 91, 474-480.	2.3	106
575	Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. <i>International Journal of Cancer</i> , 2001, 93, 80-84.	2.3	34
576	Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. <i>Genes Chromosomes and Cancer</i> , 2001, 31, 316-325.	1.5	75

#	ARTICLE	IF	CITATIONS
577	Gain of chromosome arm 9p is characteristic of primary mediastinal b-cell lymphoma (MBL): Comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. <i>Genes Chromosomes and Cancer</i> , 2001, 30, 393-401.	1.5	138
578	BCMSUN, a candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1p22-p31,BCMSUN-like. <i>International Journal of Cancer</i> , 2000, 88, 692-697.	2.3	15
579	Risk of false positive results in comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 353-357.	1.5	28
580	Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2000, 343, 1910-1916.	13.9	2,967
581	Chromosomal Aberrations in Lymphomas of the Gastrointestinal Tract. <i>Leukemia and Lymphoma</i> , 1999, 36, 25-32.	0.6	3
582	Mapping of the breakpoints on the short arm of chromosome 17 in neoplasms with an i(17q). , 1999, 25, 230-240.		37
583	Deletions below 10 megabasepairs are detected in comparative genomic hybridization by standard reference intervals. , 1999, 25, 410-413.		119
584	Exclusive Detection of the t(11;18)(q21;q21) in Extranodal Marginal Zone B Cell Lymphomas (MZBL) of MALT Type in Contrast to other MZBL and Extranodal Large B Cell Lymphomas. <i>American Journal of Pathology</i> , 1999, 155, 1817-1821.	1.9	124
585	Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. <i>Oncogene</i> , 1998, 16, 1891-1897.	2.6	139
586	Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. <i>Nature Medicine</i> , 1997, 3, 1155-1159.	15.2	243
587	High incidence of a second BCR-ABL fusion in chronic myeloid leukemia revealed by interphase cytogenetic analysis on blood and bone marrow smears. <i>Cancer Genetics and Cytogenetics</i> , 1996, 87, 107-111.	1.0	9
588	Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 1996, 89, 153-156.	1.0	5
589	CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1995, 91, 865-870.	1.2	20
590	Comparative genomic hybridization in the investigation of myeloid leukemias. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 193-200.	1.5	56
591	Molecular Cytogenetic Analysis of RB-1 Deletions in Chronic B-Cell Leukemias. <i>Leukemia and Lymphoma</i> , 1994, 16, 97-103.	0.6	24
592	APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with bcl-2 oncogene expression. <i>European Journal of Immunology</i> , 1993, 23, 702-708.	1.6	178
593	Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. <i>Human Genetics</i> , 1993, 90, 590-610.	1.8	544
594	Biological Response Modifiers Render Tumor Cells Susceptible to Autologous Effector Mechanisms by Influencing Adhesion Receptors. <i>Leukemia and Lymphoma</i> , 1993, 10, 25-33.	0.6	11

#	ARTICLE	IF	CITATIONS
595	Recurring chromosome abnormalities in Hodgkin's disease. <i>Genes Chromosomes and Cancer</i> , 1992, 5, 392-398.	1.5	43